Faculty, Staff and Student Publications
Publication Date
12-31-2024
Journal
Biostatistics
DOI
10.1093/biostatistics/kxae034
PMID
39275895
PMCID
PMC11823184
PubMedCentral® Posted Date
9-13-2024
PubMedCentral® Full Text Version
Post-print
Abstract
The schedule of administering a drug has profound impact on the toxicity and efficacy profiles of the drug through changing its pharmacokinetics (PK). PK is an innate and indispensable component of the dose-schedule optimization. Motivated by this, we propose a Bayesian PK integrated dose-schedule finding (PKIDS) design to identify the optimal dose-schedule regime by integrating PK, toxicity, and efficacy data. Based on the causal pathway that dose and schedule affect PK, which in turn affects efficacy and toxicity, we jointly model the three endpoints by first specifying a Bayesian hierarchical model for the marginal distribution of the longitudinal dose-concentration process. Conditional on the drug concentration in plasma, we jointly model toxicity and efficacy as a function of the concentration. We quantify the risk-benefit of regimes using utility-continuously updating the estimates of PK, toxicity, and efficacy based on interim data-and make adaptive decisions to assign new patients to appropriate dose-schedule regimes via adaptive randomization. The simulation study shows that the PKIDS design has desirable operating characteristics.
Keywords
Bayes Theorem, Humans, Clinical Trials, Phase I as Topic, Clinical Trials, Phase II as Topic, Pharmacokinetics, Dose-Response Relationship, Drug, Drug Administration Schedule, Computer Simulation, Models, Statistical, Research Design, dose-schedule finding, dose optimization, phase I–II trials, risk-benefit trade-off
Published Open-Access
yes
Recommended Citation
Mengyi Lu, Ying Yuan, and Suyu Liu, "A Bayesian Pharmacokinetics Integrated Phase I-II Design To Optimize Dose-Schedule Regimes" (2024). Faculty, Staff and Student Publications. 5187.
https://digitalcommons.library.tmc.edu/uthgsbs_docs/5187
Included in
Bioinformatics Commons, Biomedical Informatics Commons, Genetic Phenomena Commons, Medical Genetics Commons, Oncology Commons